**Seres Therapeutics, Inc. Posts Updated Corporate Presentation – 8-K Filing Review****

**

On January 13, 2025, Seres Therapeutics, Inc. (NASDAQ:MCRB) announced the release of an enhanced corporate presentation on its website in the “Investors and News” section. The company unveiled this updated presentation to provide stakeholders with current insights and developments. The details and contents of this presentation are included as Exhibit 99.1 in the latest 8-K SEC filing.

This public disclosure falls under Regulation FD Disclosure, marking a step towards transparency and communication with investors. While the information shared, including the aforementioned Exhibit 99.1, is intended for dissemination, it is not classified as a formal filing under the Securities Exchange Act of 1934. Neither is it intended to be integrated by reference into other filings under the Securities Act of 1933 or the Exchange Act, unless explicitly denoted.

Furthermore, with a focus on Financial Statements and Exhibits, Seres Therapeutics presented Exhibit 99.1 in conjunction with Item 7.01 of the filing. The mentioned exhibit encapsulates the essence of the company’s most recent corporate presentation as of January 2025.

The Phase 1b study results pertaining to SER-155 were specifically highlighted in the presentation. The study evidenced a remarkable 77% relative risk reduction in bacterial bloodstream infections, showcasing positive outcomes and efficacy associated with the biotherapeutic program.

As Seres Therapeutics aims to accelerate the development of SER-155, the company has expressed intentions for a strategic partnership to expedite subsequent studies in the realm of allo-HSCT and to expand the focus on multiple demographics at risk. Moreover, the company’s financial stability was underscored, with cash reserves projected to extend into the first quarter of 2026.

This disclosure signifies a pivotal moment for Seres Therapeutics, offering a glimpse into its evolving strategic endeavors and commitments to advancing biotherapeutics for critical medical needs. Investors and industry stakeholders are encouraged to delve deeper into the detailed corporate presentation for more comprehensive insights.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Seres Therapeutics’s 8K filing here.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.